Quick Answer
MAIA Biotechnology, Inc. reported Operating Income Loss of -$24.27 million for the year ending 2025.
- MAIA Biotechnology, Inc. showed a decrease of -43.1% in Operating Income Loss from 2024 to 2025.
- This data is from MAIA Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: -$2.23 million | Q1 2022: -$3.44 million | Q2 2022: -$3.44 million | Q3 2022: -$5.10 million | Q1 2023: -$4.18 million | Q2 2023: -$4.66 million | Q3 2023: -$4.96 million | Q1 2024: -$3.95 million | Q2 2024: -$3.82 million | Q3 2024: -$4.19 million | Q1 2025: -$5.43 million | Q2 2025: -$5.17 million | Q3 2025: -$9.36 million.
- Over the full 5 years of available data (2021 to 2025), MAIA Biotechnology, Inc.'s Operating Income Loss has declined by 211.7%.
- Historical annual values: Fiscal year 2025: -$24.27 million | Fiscal year 2024: -$16.96 million | Fiscal year 2023: -$20.18 million | Fiscal year 2022: -$16.18 million | Fiscal year 2021: -$7.79 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: